13 stories found
Arrowhead Pharmaceuticals announced that its experimental drug plozasiran significantly reduced acute pancreatitis episodes in Phase 3 trials for patients with severe hypertriglyceridemia. The company now intends to submit a regulatory filing based on these clinical findings.
Arrowhead Pharmaceuticals presented highlights from its Q3 earnings call, discussing key financial figures and advancements in its pipeline.
Ionis Pharmaceuticals saw its stock drop following competitor Arrowhead Pharmaceuticals' announcement of a successful late-stage trial for its lipid-lowering drug.
Several companies, including ATN International, EVERTEC, Montrose Environmental, Phibro Animal, UGI, and TKO, have released their latest quarterly financial results. While some companies reported earnings that beat analyst expectations, others missed revenue or EPS forecasts.
Billionaire Ken Fisher is making significant investments in the pharmaceutical sector, with Arrowhead Pharmaceuticals Inc. (ARWR) highlighted as a key holding.
Investors are closely monitoring clinical developments for Arrowhead's experimental therapy Plozasiran, which could significantly impact the biotech firm's valuation and market standing.
An analysis explores whether Arrowhead Pharmaceuticals stock is a smart investment following its transition to a commercial company.
Following recent Q1 updates, analysts from Morgan Stanley, Canaccord, Deutsche Bank, and Bernstein have adjusted price targets for several companies. This includes both increases for firms like NextEra Energy, Park Hotels & Resorts, Venture Global, Devon Energy, Golar LNG, ConocoPhillips, Chevron, and Arrowhead Pharmaceuticals, and cuts for Joby Aviation and Baker Hughes, with Canaccord citing a disappointing event for Regeneron Pharmaceuticals.
Arrowhead Pharmaceuticals (ARWR) has received a 'Buy' rating, based on the promising potential of its metabolic disease pipeline.
Arrowhead Pharmaceuticals announced plans to submit a supplemental New Drug Application (sNDA) for its drug SHASTA by the end of 2026, following trial results that showed significant triglyceride reductions and fewer pancreatitis events.
Arrowhead Pharmaceuticals (ARWR) stock reached a new high as its drug Plozasiran moves closer to expanded commercialization.
Arrowhead Pharmaceuticals expects to release topline data for its SHASTA-3/4 trials in the third quarter and plans to submit an sNDA for SHTG before the end of 2026.
Arrowhead Pharmaceuticals has received an upgrade from Morgan Stanley, citing upcoming catalysts as the reason for the improved rating.